413 related articles for article (PubMed ID: 28625364)
1. Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors.
Connelly S; Mortenson DE; Choi S; Wilson IA; Powers ET; Kelly JW; Johnson SM
Bioorg Med Chem Lett; 2017 Aug; 27(15):3441-3449. PubMed ID: 28625364
[TBL] [Abstract][Full Text] [Related]
2. Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy).
Cho Y; Baranczak A; Helmke S; Teruya S; Horn EM; Maurer MS; Kelly JW
Amyloid; 2015; 22(3):175-80. PubMed ID: 26193961
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization.
Green NS; Palaninathan SK; Sacchettini JC; Kelly JW
J Am Chem Soc; 2003 Nov; 125(44):13404-14. PubMed ID: 14583036
[TBL] [Abstract][Full Text] [Related]
4. Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis.
Green NS; Foss TR; Kelly JW
Proc Natl Acad Sci U S A; 2005 Oct; 102(41):14545-50. PubMed ID: 16195386
[TBL] [Abstract][Full Text] [Related]
5. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade.
Bulawa CE; Connelly S; Devit M; Wang L; Weigel C; Fleming JA; Packman J; Powers ET; Wiseman RL; Foss TR; Wilson IA; Kelly JW; Labaudinière R
Proc Natl Acad Sci U S A; 2012 Jun; 109(24):9629-34. PubMed ID: 22645360
[TBL] [Abstract][Full Text] [Related]
6. Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma.
Nelson LT; Paxman RJ; Xu J; Webb B; Powers ET; Kelly JW
Amyloid; 2021 Mar; 28(1):24-29. PubMed ID: 32811187
[TBL] [Abstract][Full Text] [Related]
7. Specific disruption of transthyretin(105-115) fibrilization using "stabilizing" inhibitors of transthyretin amyloidogenesis.
Liang Y; Ore MO; Morin S; Wilson DJ
Biochemistry; 2012 Apr; 51(16):3523-30. PubMed ID: 22482799
[TBL] [Abstract][Full Text] [Related]
8. Repurposing Benzbromarone for Familial Amyloid Polyneuropathy: A New Transthyretin Tetramer Stabilizer.
Cotrina EY; Oliveira Â; Leite JP; Llop J; Gales L; Quintana J; Cardoso I; Arsequell G
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32998442
[TBL] [Abstract][Full Text] [Related]
9. A substructure combination strategy to create potent and selective transthyretin kinetic stabilizers that prevent amyloidogenesis and cytotoxicity.
Choi S; Reixach N; Connelly S; Johnson SM; Wilson IA; Kelly JW
J Am Chem Soc; 2010 Feb; 132(4):1359-70. PubMed ID: 20043671
[TBL] [Abstract][Full Text] [Related]
10. Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses.
Connelly S; Choi S; Johnson SM; Kelly JW; Wilson IA
Curr Opin Struct Biol; 2010 Feb; 20(1):54-62. PubMed ID: 20133122
[TBL] [Abstract][Full Text] [Related]
11. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses.
Johnson SM; Wiseman RL; Sekijima Y; Green NS; Adamski-Werner SL; Kelly JW
Acc Chem Res; 2005 Dec; 38(12):911-21. PubMed ID: 16359163
[TBL] [Abstract][Full Text] [Related]
12. Recent progress in the understanding and treatment of transthyretin amyloidosis.
Sekijima Y
J Clin Pharm Ther; 2014 Jun; 39(3):225-33. PubMed ID: 24749898
[TBL] [Abstract][Full Text] [Related]
13. Potent and selective structure-based dibenzofuran inhibitors of transthyretin amyloidogenesis: kinetic stabilization of the native state.
Petrassi HM; Johnson SM; Purkey HE; Chiang KP; Walkup T; Jiang X; Powers ET; Kelly JW
J Am Chem Soc; 2005 May; 127(18):6662-71. PubMed ID: 15869287
[TBL] [Abstract][Full Text] [Related]
14. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.
Maurer MS; Grogan DR; Judge DP; Mundayat R; Packman J; Lombardo I; Quyyumi AA; Aarts J; Falk RH
Circ Heart Fail; 2015 May; 8(3):519-26. PubMed ID: 25872787
[TBL] [Abstract][Full Text] [Related]
15. AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin.
Penchala SC; Connelly S; Wang Y; Park MS; Zhao L; Baranczak A; Rappley I; Vogel H; Liedtke M; Witteles RM; Powers ET; Reixach N; Chan WK; Wilson IA; Kelly JW; Graef IA; Alhamadsheh MM
Proc Natl Acad Sci U S A; 2013 Jun; 110(24):9992-7. PubMed ID: 23716704
[TBL] [Abstract][Full Text] [Related]
16. Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses.
Sekijima Y; Kelly JW; Ikeda S
Curr Pharm Des; 2008; 14(30):3219-30. PubMed ID: 19075702
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of quinolone derivatives as transthyretin amyloidogenesis inhibitors and fluorescence sensors.
Reum Han A; Hee Jeon E; Woo Kim K; Ki Lee S; Ohn CY; Jean Park S; Sook Kang N; Koo TS; Bum Hong K; Choi S
Bioorg Med Chem; 2022 Jan; 53():116550. PubMed ID: 34890995
[TBL] [Abstract][Full Text] [Related]
18. Tafamidis for transthyretin amyloidosis.
de Lartigue J
Drugs Today (Barc); 2012 May; 48(5):331-7. PubMed ID: 22645721
[TBL] [Abstract][Full Text] [Related]
19. Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity.
Sant'Anna R; Gallego P; Robinson LZ; Pereira-Henriques A; Ferreira N; Pinheiro F; Esperante S; Pallares I; Huertas O; Almeida MR; Reixach N; Insa R; Velazquez-Campoy A; Reverter D; Reig N; Ventura S
Nat Commun; 2016 Feb; 7():10787. PubMed ID: 26902880
[TBL] [Abstract][Full Text] [Related]
20. Tafamidis (Vyndaqel): a light for FAP patients.
Nencetti S; Rossello A; Orlandini E
ChemMedChem; 2013 Oct; 8(10):1617-9. PubMed ID: 24000164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]